P-145 Welcome 54-week Open-label Extension: Efficacy of Certolizumab Pegol in Crohnʼs Disease Patients With Secondary Failure and Anti-infliximab Antibodies

Journal article

Peer reviewed

Brian Feagan, William Sandborn, Bosny Pierre-Louis, Christopher Fourment and Maria Abreu

Inflammatory bowel diseases, Vol.19, p.S82

2013-12

Metrics

7 Record Views

Title: P-145 Welcome 54-week Open-label Extension
Creators: Brian Feagan
William Sandborn
Bosny Pierre-Louis
Christopher Fourment
Maria Abreu
Publication Details: Inflammatory bowel diseases, Vol.19, p.S82
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Gastroenterology
Language: English
Resource Type: Journal article
Record Identifier: 991031598606502976